Prediction and Prevention - Medicine in the Age of Information (Panel)
Moderated by Chris Yoo, Founder, Chairman & CEO, Systems Imagination;
Panelists- Ron Korn, MD PhD, Founder, Chairman and Chief Medical
Officer, Imaging Endpoints; Scott Jenkins, PhD, Chairman
& CEO, RealTime Oncology, Todd Huffman, CEO, 3Scan
Purpose Driven Innovation
Presented by Matthew Likens, President and Chief Executive
Officer, Ulthera division of Merz Pharma
Mr. Likens joined Ulthera in July of 2006. He spent more than twenty years in domestic and international sales, marketing and general management roles at Baxter Healthcare Corporation, culminating in the positions of President of Baxter Biotech North America, then President of Baxter’s Renal Division in the U.S. In 2001, Mr. Likens joined GMP Companies, and was President of GMP Wireless Medicine, Inc.
White Space Enterprise Corporation
Frederic Zenhausern, Ph.D., MBA, President, WhiteSpace Enterprise Corporation (“WSE”) is developing platform technologies and commercial products combining methods from physical sciences and integrated microsystems for automating and miniaturizing the workflow processing of biological specimens. These platforms have broad applications for point-of-care testing that will enable precise and mobile health analysis ranging from rapid DNA analysis to predictive biomarkers for molecular diagnostics. The company’s design of genomic and proteomic biomarkers panel for monitoring radiation sensitivities will provide new ways for guiding personalized treatment in radiotherapies that that will improve value in healthcare delivery.
Reaching Your Destination – An Arizona Success StoryDarryl Baker, Chief Financial Officer of Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company based in Chandler, Arizona that develops and commercializes innovative supportive care products. In one of the hottest years for biotech IPO’s in recent memory, Insys was the top performing IPO of 2013 with over 380% growth in shareholder value and a market cap in excess of $800 million at the end of the year.Join us as Darryl Baker, Chief Financial Officer of Insys, shares insights from their journey and takes a look at the road ahead.Learn more about Darryl.
Remembering PolioPolio, or poliomyelitis, is an infectious viral disease that can strike at any age and affects a person’s nervous system. In the late 1940s to the early 1950s, polio crippled an average of more than 35,000 people in the United States each year; it was one of the most feared diseases of the twentieth century. Thanks to the polio vaccine, dedicated health care professionals, and parents who vaccinate their children on schedule, polio has been eliminated in this country for more than 30 years. (Source: CDC) Today the US is home to approximately 1 million polio survivors. Join our panelists in a look at what polio was, the impacts polio has on Americans today, and the importance of vaccinations in our ever shrinking world.Moderator: Gapar Laca, State Government Affairs Director at GlaxoSmithKlinePanelists: David Larwood, CEO, President – Valley Fever Solutions, Debbie McCune Davis, Executive Director, The Arizona Partnership for Immunization (TAPI)
Clinical Trials in Arizona - Capstone Therapeutics
Capstone Therapeutics Corp. is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). Presenter- Jock Holliman